Reported 3 days ago
Jim Cramer expressed cautious optimism about Sarepta Therapeutics Inc. (NASDAQ: SRPT) regarding its RNA therapies but later acknowledged the stock's significant decline of 68.98%. As of January 2025, Cramer has changed his stance, highlighting concerns about RNA-based therapeutic companies and advising against investing in SRPT. While SRPT shows potential, there are other AI stocks he believes might offer better returns.
Source: YAHOO